INTELLIA Lands Up to $400M Non-Dilutive Debt Facility From OrbiMed
The CRISPR company drew $75 million at closing, with $325 million more tied to milestones ahead of a planned U.S. launch of lonvo-z in hereditary angioedema.
Intellia Therapeutics (NTLA) said on September 4, 2026 that it has entered into a $400 million non-dilutive senior secured term loan facility with healthcare investment firm OrbiMed. An initial term loan of $75 million was funded at closing, with the remainder tied to milestones and mutual agreement over a five-year term.
The structure breaks down into three parts: the $75 million upfront tranche, five additional tranches totaling up to $225 million that Intellia can draw at its option upon hitting specified milestones tied primarily to lonvoguran ziclumeran, and a further $100 million available only subject to mutual agreement between the parties.
The financing is aimed at carrying the company through what it calls anticipated value inflection points, including a planned U.S. approval and commercial launch of lonvo-z as a one-time treatment for hereditary angioedema (HAE).
Chief Financial Officer Edward Dulac said lonvo-z has the potential to transform the treatment paradigm for people living with HAE as well as the future capital needs of our company, adding that the non-dilutive structure lets Intellia execute its launch plan and advance nexiguran ziclumeran in transthyretin amyloidosis. OrbiMed General Partner Matthew Rizzo described Intellia as a leader in the in vivo gene editing revolution.
Lonvo-z, formerly NTLA-2002, is an in vivo CRISPR/Cas9 candidate designed to permanently lower kallikrein by inactivating the KLKB1 gene with a single outpatient dose. It carries five regulatory designations: Orphan Drug and RMAT from the FDA, the U.K. MHRA's Innovation Passport, EMA PRIME status and Orphan Drug Designation from the European Commission.
TD Cowen acted as exclusive financial advisor to Intellia, with Goodwin Procter as legal counsel and Covington & Burling advising OrbiMed. Full terms of the loan agreement will be filed with the SEC on a Form 8-K.
Intellia flagged the usual caveats: there is no assurance it will hit the milestones needed to access the additional $225 million, that the extra $100 million will be agreed, or that the debt-service obligations, restrictive covenants and security interests attached to the facility will not constrain it.
This is a factual summary of a public filing or press release, not investment advice. Verify all figures against the source before acting on them.
